The company expects to launch more than 20 pivotal late-stage trials this year.

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...

Pfizer is almost certain to survive the current headwinds as a business. However, the dividend may not. It will be important ...

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

What Pfizer’s recent performance tells you right now Pfizer (PFE) has drawn fresh attention after a period in which the share ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend ...

Pfizer is acquiring a pharma company that has multiple GLP-1 drugs in development. The deal may cost the company up to $7.3 billion, which is a move Pfizer can afford to make given its strong ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...